Stockreport

UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Approval Based on Phase 3 Trial Results Showing a Complete Response Rate of 58% Median Duration of Response Has Not Been ReachedTherapy Provides an Effective, Kidney-Spa [Read more]